Novel Biomarkers in Alzheimer's Disease

doi:10.3390/books978-3-03943-904-1

dc.contributor.editor	Villa, Chiara
dc.date.accessioned	2021-05-01T15:08:09Z
dc.date.available	2021-05-01T15:08:09Z
dc.date.issued	2021
dc.identifier	ONIX_20210501_9783039439034_107
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/68362
dc.description.abstract	Alzheimer’s disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD.
dc.language	English
dc.subject.classification	thema EDItEUR::M Medicine and Nursing	en_US
dc.subject.other	flotillin
dc.subject.other	Alzheimer’s disease
dc.subject.other	biomarker
dc.subject.other	exosomes
dc.subject.other	beta-amyloid
dc.subject.other	Tau
dc.subject.other	aging
dc.subject.other	biomarkers
dc.subject.other	cytokines
dc.subject.other	cognitive decline
dc.subject.other	metabolomics
dc.subject.other	neuroinflammation
dc.subject.other	multivariate analysis
dc.subject.other	physical performance
dc.subject.other	person-tailored
dc.subject.other	PET/CT
dc.subject.other	(18F)FDG
dc.subject.other	neuropsychological assessment
dc.subject.other	APP mutations
dc.subject.other	APOE alleles
dc.subject.other	PSEN1
dc.subject.other	PSEN2
dc.subject.other	germline mutations
dc.subject.other	late onset AD
dc.subject.other	early onset AD
dc.subject.other	familial AD
dc.subject.other	genetics of AD
dc.subject.other	mitochondrial spare respiratory capacity
dc.subject.other	mitochondrial
dc.subject.other	membrane potential
dc.subject.other	glycolytic reserve
dc.subject.other	semantic memory
dc.subject.other	phonemic fluency
dc.subject.other	episodic memory
dc.subject.other	neuropsychology
dc.subject.other	neuroimaging
dc.subject.other	Alzheimer's disease
dc.subject.other	mild cognitive impairment
dc.subject.other	EEG
dc.subject.other	TMS
dc.subject.other	obesity
dc.subject.other	diabetes
dc.subject.other	inflammation
dc.subject.other	Amyloid Beta
dc.subject.other	mitochondrial dysfunction
dc.subject.other	nutrition
dc.subject.other	omega-3 fatty acids
dc.subject.other	antioxidant
dc.subject.other	carotenoids
dc.subject.other	vitamin E
dc.subject.other	cognition
dc.subject.other	older adults
dc.subject.other	ageing
dc.subject.other	subjective cognitive decline
dc.subject.other	clock genes
dc.subject.other	Clock
dc.subject.other	ApoE
dc.subject.other	cardiovascular risk factors
dc.subject.other	Alzheimer disease
dc.subject.other	semantic priming
dc.subject.other	amyloid beta
dc.subject.other	cerebrospinal fluid
dc.subject.other	amyloid beta peptide
dc.subject.other	total tau
dc.subject.other	phosphorylated tau
dc.subject.other	diagnosis
dc.subject.other	drug development
dc.subject.other	clinical trials
dc.subject.other	diagnostic research
dc.subject.other	virus
dc.subject.other	bacteria
dc.subject.other	dementia
dc.subject.other	blood
dc.subject.other	behavioral and psychological symptoms of dementia (BPSD)
dc.subject.other	Alzheimer’s disease (AD)
dc.subject.other	neuropsychiatry inventory scale (NPI)
dc.subject.other	endophenotypes
dc.subject.other	CART analysis
dc.subject.other	MTHFR
dc.subject.other	APOE
dc.subject.other	COMT
dc.subject.other	genetic variants
dc.subject.other	early diagnosis
dc.subject.other	biofluids
dc.subject.other	amyloid cascade hypothesis
dc.subject.other	glucose metabolism
dc.subject.other	adipose tissue dysfunction
dc.subject.other	energetic metabolism
dc.subject.other	lysosomes dysfunction
dc.subject.other	Type-3-Diabetes
dc.subject.other	neurodegeneration
dc.subject.other	amyloid
dc.subject.other	tau
dc.subject.other	soluble TREM2
dc.subject.other	NfL
dc.subject.other	Multiplex
dc.subject.other	SiMoA
dc.subject.other	diagnostics
dc.subject.other	messenger RNA
dc.subject.other	microRNA
dc.subject.other	neurotropic microbes
dc.subject.other	precision medicine
dc.subject.other	prognostics
dc.subject.other	synaptic biomarkers
dc.subject.other	neurofilament light chain
dc.subject.other	n/a
dc.title	Novel Biomarkers in Alzheimer's Disease
dc.type	book
oapen.identifier.doi	10.3390/books978-3-03943-904-1
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn	9783039439034
oapen.relation.isbn	9783039439041
oapen.pages	442
oapen.place.publication	Basel, Switzerland

Files in this item

Files	Size	Format	View
There are no files associated with this item.

This item appears in the following Collection(s)

Imported or submitted locally

Show simple item record

Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/